跳至主要内容
临床试验/ISRCTN84335288
ISRCTN84335288已完成未知

A randomised controlled trial investigating the pharmacodynamic effect of TicagrElor Monotherapy on PLATElet reactivity in patients with coronary artery disease

niversity Hospitals Bristol NHS Foundation Trust0 个研究点目标入组 110 人开始时间: 2014年6月23日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
110

研究概览

简要总结

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Patient is treated with dual antiplatelet therapy comprising aspirin and clopidogrel for a minimum of 4 weeks (amended from: for 12 months as of 31/03/2016)
  • 2. The patient is scheduled to stop dual antiplatelet therapy and continue with aspirin monotherapy

排除标准

  • 1. Contraindication to dual antiplatelet therapy
  • 2. Interruption of dual antiplatelet therapy because of bleeding events or increased bleeding risk
  • 3. Contraindications to the use of ticagrelor
  • 4. Pregnant and or lactating women
  • 5. Women with child bearing potential (i.e. not sterilised or not post-menopausal) who are unwilling to use contraception
  • 6. Men with a spouse or partner with child bearing potential unless the participant has agreed to use condoms

研究者

发起方
niversity Hospitals Bristol NHS Foundation Trust

相似试验